Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus
about
Protease-resistant peptide design-empowering nature's fragile warriors against HIVStructural and biological mimicry of protein surface recognition by / -peptide foldamersDesign of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to ResistanceBroad Distribution of Energetically Important Contacts across an Extended Protein InterfaceThe M-T Hook Structure Is Critical for Design of HIV-1 Fusion InhibitorsBroad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor SifuvirtideDiscovery of Critical Residues for Viral Entry and Inhibition through Structural Insight of HIV-1 Fusion Inhibitor CP621-652Enhancement of α-Helix Mimicry by an α/β-Peptide Foldamer via Incorporation of a Dense Ionic Side-Chain ArrayAsymmetric deactivation of HIV-1 gp41 following fusion inhibitor bindingAnalysis and prediction of highly effective antiviral peptides based on random forestsA novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitroA general strategy to endow natural fusion-protein-derived peptides with potent antiviral activityImproved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide StrategyDesign and characterization of swapped-domain constructs of HIV-1 glycoprotein-41 as receptors for drug discovery.Multivalent presentation of antihantavirus peptides on nanoparticles enhances infection blockadeStable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors.Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cellsTwo M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK.Origins of resistance to the HIVgp41 viral entry inhibitor T20.Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases.Viral entry inhibitors targeted to the membrane site of action.Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicidesMechanism of resistance to S138A substituted enfuvirtide and its application to peptide designHydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeuticDiscovery of entry inhibitors for HIV-1 via a new de novo protein design framework.Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses.Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodiesCovalent fusion inhibitors targeting HIV-1 gp41 deep pocket.Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.HIV entry inhibitors and their potential in HIV therapyDramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation.Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potencyDisruption of Bcr-Abl coiled coil oligomerization by design.Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor designTargeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapyMechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 PocketInteractions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.
P2860
Q27010058-1C8B9E49-5C14-4796-A4E3-7F626D6BF355Q27657158-26BC33D2-FF28-4123-B1C0-DB3F42FABA4EQ27664086-704B3EB6-64B6-4D69-9C4C-A1AB34F0021DQ27666255-17450F0D-2BC9-41C6-877B-85D7305FA6F6Q27671434-2B57BB19-FA3C-4889-BB78-B269CF92F49BQ27676641-823F0DA7-0B16-4928-B78B-B289066BA129Q27678581-B23D7BFA-5F1F-4B95-840F-7772DE60D640Q27678660-389EA02C-05FF-4F18-8C9B-5371774F913AQ28471980-05088247-71E2-41ED-B94D-A5FC72319641Q28535105-9979C06E-03C3-43E5-9980-DEC3D9402F9BQ28728917-85758A90-0D08-4777-950B-C1DF7481AA0DQ28729918-3AC42AB5-A471-435E-B6EF-918F2758A7E5Q30661709-A6674F85-B5CF-4E62-8C99-1ADB72347B48Q30912819-0D704A9A-A6C4-4F92-878B-8E2FF7521301Q33327051-6E1D393E-AD45-4DA3-976F-F30D50AD9E5AQ33429777-B5EB01AF-4EFE-4D80-8F07-29B66A3C4832Q33613769-B2AD6A44-E879-4C04-BA73-D7863327B6E4Q33713101-4E3B3027-56AB-48EC-A1A1-4DAD511A48B1Q33840121-BB5CFCA0-48CE-4A75-9512-5FCD83A44226Q33951142-F070E66D-C99B-496A-BDD2-E89EE4D48F25Q33990602-5CEA737E-C3BC-448E-83A9-52BA4E30D271Q34055847-2ABFBC0D-3AED-4E4E-9D4B-76E8C00962DDQ34059855-0B76C610-B8C9-4292-8BD3-50F8C8EEB278Q34069846-F73624C0-7CB8-4450-BD51-A70EE3342F27Q34150117-361003FD-1666-4745-8824-AF82B62D1518Q34182763-AE61DCA9-2697-445F-9EC7-29D64333D810Q34189558-1A747D58-19A0-4436-9B10-F59B01953D9DQ34229664-B44F2FE2-0661-4E08-A72A-3982671D4F6CQ34298481-CF16DBD0-1CEE-4EDA-96EE-FE0CD0014AB9Q34385987-0B102B7B-67D1-48A0-AE2B-571216B0C476Q34517381-91C190D9-C4BE-4081-969F-E310921A88CEQ34536817-BD9F6950-B773-44E3-BF41-338E7DF9CE36Q34595921-F9D3F846-4DAA-410F-90F8-757D5F22FE61Q34683447-CED1AF13-3E74-4BB6-889E-12CB1A370886Q34800822-08AB5D63-DBC6-49F7-B2BB-FBE1A2EC8677Q35145034-F59AF171-DA83-4FAB-ABFD-A206D0CA7104Q35563298-BF57D124-173C-4D82-99B5-D4C216EB5203Q35615810-0F05F574-0BC3-4595-BF2C-D51C7F0A5417Q35641194-AAA99FD2-41FB-46F1-BE63-2C297F2892D8Q35787743-29749BC5-84C5-4551-9E6A-A08E40F3C73E
P2860
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Design of helical, oligomeric ...... st enfuvirtide-resistant virus
@ast
Design of helical, oligomeric ...... st enfuvirtide-resistant virus
@en
type
label
Design of helical, oligomeric ...... st enfuvirtide-resistant virus
@ast
Design of helical, oligomeric ...... st enfuvirtide-resistant virus
@en
prefLabel
Design of helical, oligomeric ...... st enfuvirtide-resistant virus
@ast
Design of helical, oligomeric ...... st enfuvirtide-resistant virus
@en
P2093
P2860
P356
P1476
Design of helical, oligomeric ...... st enfuvirtide-resistant virus
@en
P2093
Donna K Davison
Jennifer E Seedorff
John J Dwyer
Karen L Wilson
Mary K Delmedico
Michael L Greenberg
Nicolai A Tvermoes
Stephanie A Freel
Stephen A Wring
Thomas J Matthews
P2860
P304
12772-12777
P356
10.1073/PNAS.0701478104
P407
P577
2007-07-19T00:00:00Z